Literature DB >> 25895986

CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.

Gaia Sciaranghella1, Cuiwei Wang2, Haihong Hu2, Kathryn Anastos3, Zaher Merhi4, Marek Nowicki5, Frank Z Stanczyk6, Ruth M Greenblatt7, Mardge Cohen8, Elizabeth T Golub9, D Heather Watts10, Galit Alter1, Mary A Young2, Athe M N Tsibris11.   

Abstract

Human immunodeficiency virus (HIV) infectivity increases as receptor/coreceptor expression levels increase. We determined peripheral CD4, CCR5, and CXCR4 expression levels in HIV-uninfected women who used depot medroxyprogesterone acetate (DMPA; n = 32), the levonorgestrel-releasing intrauterine device (LNG-IUD; n = 27), oral contraceptive pills (n = 32), or no hormonal contraception (n = 33). The use of LNG-IUD increased the proportion of CD4(+) and CD8(+) T cells that expressed CCR5; increases in the magnitude of T-cell subset CCR5 expression were observed with DMPA and LNG-IUD use (P < .01 for all comparisons). LNG-IUD and, to a lesser extent, DMPA use were associated with increased peripheral T-cell CCR5 expression.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CCR5; CD4; CXCR4; HIV-1; hormonal contraception; levonorgestrel; medroxyprogesterone acetate; oral contraceptive pills; peripheral blood mononuclear cells

Mesh:

Substances:

Year:  2015        PMID: 25895986      PMCID: PMC4601918          DOI: 10.1093/infdis/jiv233

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.

Authors:  F Z Stanczyk; M Hiroi; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Contraception       Date:  1975-09       Impact factor: 3.375

2.  Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.

Authors:  Beata Seeber; Stephanie C Ziehr; Andreas Gschlieβer; Aandrea Gschliesser; Christina Moser; Verena Mattle; Christoph Seger; Andrea Griesmacher; Nicole Concin; Hans Concin; Ludwig Wildt
Journal:  Contraception       Date:  2012-03-06       Impact factor: 3.375

Review 3.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

4.  Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

Authors:  Emily J Platt; James P Durnin; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.

Authors:  M Hiroi; F Z Stanczyk; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Steroids       Date:  1975-09       Impact factor: 2.668

6.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.

Authors:  Renee Heffron; Deborah Donnell; Helen Rees; Connie Celum; Nelly Mugo; Edwin Were; Guy de Bruyn; Edith Nakku-Joloba; Kenneth Ngure; James Kiarie; Robert W Coombs; Jared M Baeten
Journal:  Lancet Infect Dis       Date:  2011-10-03       Impact factor: 25.071

7.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

9.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.

Authors:  Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Jared M Baeten; Joelle Brown; Angela M Crook; Lut Van Damme; Sinead Delany-Moretlwe; Suzanna C Francis; Barbara A Friedland; Richard J Hayes; Renee Heffron; Saidi Kapiga; Quarraisha Abdool Karim; Stephanie Karpoff; Rupert Kaul; R Scott McClelland; Sheena McCormack; Nuala McGrath; Landon Myer; Helen Rees; Ariane van der Straten; Deborah Watson-Jones; Janneke H H M van de Wijgert; Randy Stalter; Nicola Low
Journal:  PLoS Med       Date:  2015-01-22       Impact factor: 11.069

View more
  15 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection.

Authors:  Carley Tasker; Amy Davidow; Natalie E Roche; Theresa L Chang
Journal:  Immunohorizons       Date:  2017-11-01

3.  Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.

Authors:  Elizabeth H Byrne; Melis N Anahtar; Kathleen E Cohen; Amber Moodley; Nikita Padavattan; Nasreen Ismail; Brittany A Bowman; Gregory S Olson; Amanda Mabhula; Alasdair Leslie; Thumbi Ndung'u; Bruce D Walker; Musie S Ghebremichael; Krista L Dong; Douglas S Kwon
Journal:  Lancet Infect Dis       Date:  2015-12-24       Impact factor: 25.071

4.  People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells.

Authors:  Louise E van Eekeren; Vasiliki Matzaraki; Zhenhua Zhang; Lisa van de Wijer; Marc J T Blaauw; Marien I de Jonge; Linos Vandekerckhove; Wim Trypsteen; Leo A B Joosten; Mihai G Netea; Quirijn de Mast; Hans J P M Koenen; Yang Li; André J A M van der Ven
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

5.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

6.  Transgender populations and HIV: unique risks, challenges and opportunities.

Authors:  Tanyaporn Wansom; Thomas E Guadamuz; Sandhya Vasan
Journal:  J Virus Erad       Date:  2016-04-01

7.  Contraceptive challenges in adolescents living with or at risk of HIV.

Authors:  Nadia Kancheva Landolt; Torsak Bunupuradah; Surasith Chaithongwongwatthana
Journal:  J Virus Erad       Date:  2016-04-01

8.  A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.

Authors:  Guillermo Villegas; Giulia Calenda; Shweta Ugaonkar; Shimin Zhang; Larisa Kizima; Olga Mizenina; Agegnehu Gettie; James Blanchard; Michael L Cooney; Melissa Robbiani; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

9.  Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.

Authors:  N E Quispe Calla; R D Vicetti Miguel; P N Boyaka; L Hall-Stoodley; B Kaur; W Trout; S D Pavelko; T L Cherpes
Journal:  Mucosal Immunol       Date:  2016-03-23       Impact factor: 7.313

10.  Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.

Authors:  Michelle F Maritz; Roslyn M Ray; Alexis J Bick; Michele Tomasicchio; John G Woodland; Yashini Govender; Chanel Avenant; Janet P Hapgood
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.